Table 1. Baseline Demographic and Clinical Characteristics of Subjects Included in the Analysis.
| Subjects who underwent non-therapeutic catheter-based angiogram (n = 89) | Subjects randomized to intravenous rt-PA alone (n = 222) | p-value | |
|---|---|---|---|
| Age (years) [median (range)] | 69 (35–83) | 68 (23–84) | 0.34 |
| Gender Men Women |
48 (53.9) 41 (46.1) |
122 (55) 100 (45) |
0.88 |
| Race or ethnic group African–American White Other ethnicities |
12(13.4) 73 (82) 4 (4.6) |
19 (8.6) 190 (85.6) 23 (5.8) |
0.2 |
| NIHSS score [median (range)] | 15 (7–39) | 16 (8–30) | 0.04** |
| Baseline NIHSS score strata ≤9 10–19 ≥20 |
2 (2.2) 70 (78.7) 17 (19.1) |
4 (1.8) 146 (65.8) 72 (32.4) |
0.05** |
| Baseline ASPECTS 8, 9, or 10 | 73 (82) | 131 (59) | <0.001** |
| Time interval between symptom onset to ED arrival (minutes ±SD) | 57.7 ±29.4 | 57 ±27.3 | 0.87 |
| Time interval between symptom onset to randomization (minutes ±SD) | 145.5 ±34.8 | 143.1 ±35.3 | 0.6 |
| Time interval between ED arrival to IV rt-PA initiation (minutes ±SD) | 65.5 ±22.9 | 64.7 ±28 | 0.82 |
| Vascular risk factors Hypertension Diabetes mellitus Congestive heart failure Coronary artery disease Cigarette smoking Atrial fibrillation History of myocardial infarction Hyperlipidemia |
64 (71.9) 25 (28.1) 13 (14.6) 23 (25.8) 22 (24.7) 25 (28.1) 15 (16.9) 50 (56.2) |
171 (77) 54 (24.3) 31 (14) 72 (32.4) 63 (28.4) 70 (31.5) 36 (16.2) 112 (50.5) |
0.64 0.8 0.12 0.35 0.51 0.55 0.68 0.6 |
| Modified Rankin scale (status prior to stroke) 0 1 2 |
80 (89.9) 4 (4.5) 5 (5.6) |
197 (88.7) 21 (9.5) 4 (1.8) |
0.08 |
|
Presumptive stroke location Left hemisphere Right hemisphere Brain Stem or cerebellum Unknown or multiple locations |
55 (61.8) 30 (33.7) 3 (3.4) 1 (1.1) |
106 (47.7) 109 (49.1) 4 (1.8) 3 (1.4) |
0.07 |
| Baseline systolic blood pressure (mmHg ±SD) | 150 ±22.8 | 147.4 ±23.9 | 0.38 |
| International normalized ratio [median (range)] | 1 (0.9–1.7) | 1 (0.9–1.7) | 0.85 |
| Baseline serum glucose (mmol/liter) (mean ±SD) | 7.4 ±2.6 | 7.6 ±3.1 | 0.52 |
| Antiplatelet use at baseline* | 40 (44.9) | 108 (48.6) | 0.68 |
| Statin use at baseline* | 32 (36) | 83 (37.4) | 0.6 |
Abbreviations: NIHSS: National Institutes of Health Stroke Scale; ASPECTS: Alberta stroke program early CT score; SD: standard deviation; ED: emergency department; rt-PA: recombinant tissue plasminogen activator.
*
Antiplatelet and statin use at baseline: is defined as ongoing use at the day of randomization or with discontinuation date within two weeks of randomization.
**
Significant p-values at <0.05 level of significance.